NBTX Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat DBV Technologies SA's return on equity of --.

Nanobiotix SA has a consensus price target of $10.47, signalling upside risk potential of 249.64%. On the other hand DBV Technologies SA has an analysts' consensus of $22.11 which suggests that it could grow by 534.36%. Given that DBV Technologies SA has higher upside potential than Nanobiotix SA, analysts believe DBV Technologies SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.640, suggesting its less volatile than the S&P 500 by 36.023%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than DBV Technologies SA's net income of -$30.4M. Notably, Nanobiotix SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.25x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Genfit SA's return on equity of --.

Nanobiotix SA has a consensus price target of $10.47, signalling upside risk potential of 249.64%. On the other hand Genfit SA has an analysts' consensus of -- which suggests that it could grow by 175.63%. Given that Nanobiotix SA has higher upside potential than Genfit SA, analysts believe Nanobiotix SA is more attractive than Genfit SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.46%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Genfit SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.25x versus 2.70x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Innate Pharma SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.

Nanobiotix SA has a consensus price target of $10.47, signalling upside risk potential of 249.64%. On the other hand Innate Pharma SA has an analysts' consensus of $7.41 which suggests that it could grow by 298.5%. Given that Innate Pharma SA has higher upside potential than Nanobiotix SA, analysts believe Innate Pharma SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.239, suggesting its less volatile than the S&P 500 by 76.126%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.25x versus 5.61x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Nanobiotix SA's net margin of --. Nanobiotix SA's return on equity of -- beat Inventiva SA's return on equity of --.

Nanobiotix SA has a consensus price target of $10.47, signalling upside risk potential of 249.64%. On the other hand Inventiva SA has an analysts' consensus of $12.43 which suggests that it could grow by 460.09%. Given that Inventiva SA has higher upside potential than Nanobiotix SA, analysts believe Inventiva SA is more attractive than Nanobiotix SA.

Nanobiotix SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nanobiotix SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nanobiotix SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Nanobiotix SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Nanobiotix SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Nanobiotix SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nanobiotix SA is 3.25x versus 6.64x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.